82 related articles for article (PubMed ID: 10470123)
21. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of preoperative serum sialyl Lewis X-i antigen levels in non-small cell lung cancer.
Satoh H; Ishikawa H; Yamashita YT; Takahashi H; Ishikawa S; Kamma H; Ohtsuka M; Hasegawa S
Anticancer Res; 1998; 18(4B):2865-8. PubMed ID: 9713476
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
25. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
26. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer.
Iizasa T; Chang H; Suzuki M; Otsuji M; Yokoi S; Chiyo M; Motohashi S; Yasufuku K; Sekine Y; Iyoda A; Shibuya K; Hiroshima K; Fujisawa T
Clin Cancer Res; 2004 Aug; 10(16):5361-6. PubMed ID: 15328173
[TBL] [Abstract][Full Text] [Related]
28. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G
Lung; 2001; 179(1):57-65. PubMed ID: 11479694
[TBL] [Abstract][Full Text] [Related]
30. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
31. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
Gautschi O; Bigosch C; Huegli B; Jermann M; Marx A; Chassé E; Ratschiller D; Weder W; Joerger M; Betticher DC; Stahel RA; Ziegler A
J Clin Oncol; 2004 Oct; 22(20):4157-64. PubMed ID: 15483026
[TBL] [Abstract][Full Text] [Related]
32. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.
Ulukaya E; Yilmaztepe A; Akgoz S; Linder S; Karadag M
Lung Cancer; 2007 Jun; 56(3):399-404. PubMed ID: 17316892
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of carcinoembryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung.
Fukai R; Sakao Y; Sakuraba M; Oh S; Shiomi K; Sonobe S; Saitoh Y; Miyamoto H
Eur J Cardiothorac Surg; 2007 Sep; 32(3):440-4. PubMed ID: 17643308
[TBL] [Abstract][Full Text] [Related]
34. Serum endothelial monocyte-activating polypeptide-II: a novel biomarker in patients with non-small-cell lung cancer.
Sen E; Ulger F; Kaya A; Akar N; Gonullu U
Clin Lung Cancer; 2008 May; 9(3):166-70. PubMed ID: 18621627
[TBL] [Abstract][Full Text] [Related]
35. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
36. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
37. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
38. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
39. Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment.
Eriksson P; Brattström D; Hesselius P; Larsson A; Bergström S; Ekman S; Goike H; Wagenius G; Brodin O; Bergqvist M
Neoplasma; 2006; 53(4):285-90. PubMed ID: 16830054
[TBL] [Abstract][Full Text] [Related]
40. Relationship between N-linked oligosaccharide chains of human serum immunoglobulin G and serum tumor markers with non-small cell lung cancer progression.
Kanoh Y; Ohara T; Mashiko T; Abe T; Masuda N; Akahoshi T
Anticancer Res; 2006; 26(6B):4293-7. PubMed ID: 17201147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
